The pooled results from all the DD-CKD patients showed that roxadustat significantly raised the Hb level compared with the ESAs (epoetin alfa and darbepoetin alfa) (WMD: 0.14; 95% CI: 0.05–0.23; p = 0.001; without heterogeneity [p = 0.13]; Figure 3A, Table 3). This evidence concerns the gene GSTM1 and chronic kidney disease.